BIIBStockBiogen Inc
Verdicts genuinely change. Free email alert the moment BIIB's does — no target price to set, unlike "Alert" above.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Biogen Inc (BIIB) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-31). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 456 compliant Healthcare stocks we track. See compliant Healthcare stocks →
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-03-31. BIIB files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
AAOIFI Pass 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.16% | 30.00% | Pass |
| Interest-bearing investments | 10.77% | 30.00% | Pass |
| Non-permissible income | 1.26% | 5.00% | Pass |
Usmani Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 22.53% | 33.00% | Pass |
| Interest-bearing investments | 11.47% | 33.00% | Pass |
| Non-liquid assets | 83.97% | at least 20.00% | Pass |
| Non-permissible income | 1.26% | 5.00% | Pass |
MSCI Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 22.53% | 33.33% | Pass |
| Cash + interest-bearing securities | 11.47% | 33.33% | Pass |
| Accounts receivable | 16.03% | 33.33% | Pass |
| Non-permissible income | 1.26% | 5.00% | Pass |
FTSE Pass 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 21.33% | 33.33% | Pass |
| Cash + interest-bearing securities | 11.47% | 33.33% | Pass |
| Accounts receivable | 16.03% | 50.00% | Pass |
| Non-permissible income | 1.26% | 5.00% | Pass |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 32.08% | 33.00% | Pass |
| Cash + interest-bearing securities | 16.33% | 33.00% | Pass |
| Accounts receivable | 6.48% | 33.00% | Pass |
| Non-permissible income | 1.26% | 5.00% | Pass |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 29.03% | 33.00% | Pass |
| Cash + interest-bearing securities | 14.78% | 49.00% | Pass |
| Accounts receivable | 5.87% | 49.00% | Pass |
| Non-permissible income | 1.26% | 5.00% | Pass |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 29.03% | 33.33% | Pass |
| Cash + interest-bearing securities | 14.78% | 33.33% | Pass |
| Accounts receivable | 20.65% | 49.00% | Pass |
| Non-permissible income | 1.26% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from BIIB's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $9.9B | 2025-12-31 | Revenues |
| Interest-bearing debtShort and long-term borrowings | $6.3B | 2026-03-31 | LongTermDebt, DebtCurrent |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $3.4B | 2026-03-31 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $29.5B | 2026-03-31 | Assets |
| Market capDenominator for AAOIFI | $31.4B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $27.3B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $24.2B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $125.0M | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
What changed, and when
Verdict history for BIIB. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for BIIB has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $73M | 0.0% | 2026-06-30 |
| Wahed Invest | Wahed Invest LLC | $1M | 0.1% | 2026-06-30 |
| Azzad Asset Management | Azzad Asset Management | $1M | 0.1% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 71.80 | SELL |
| Stochastic %K (14) | 95.66 | SELL |
| CCI (20) | 135.90 | SELL |
| Williams %R (14) | -4.34 | SELL |
| MACD (12,26,9) | 2.19 | BUY |
| ROC (10) | 10.41 | BUY |
| Momentum (10) | 23.83 | BUY |
| EMA (10) | 244.02 | BUY |
| SMA (10) | 242.79 | BUY |
| EMA (20) | 237.02 | BUY |
| SMA (20) | 233.38 | BUY |
| EMA (30) | 232.63 | BUY |
| SMA (30) | 229.99 | BUY |
| EMA (50) | 226.57 | BUY |
| SMA (50) | 225.10 | BUY |
| EMA (100) | 216.41 | BUY |
| SMA (100) | 214.35 | BUY |
| EMA (200) | 202.24 | BUY |
| SMA (200) | 200.11 | BUY |
About Biogen Inc
Healthcare · Drug Manufacturers - General
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-10-22
Stop 243.45 Now 252.73 Target 260.23
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 2 bearish
Average — needs more confirmation before sizing up
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 64 |
| ⏰ 4H | BULLISH | 37 |
| 🕐 1H | BULLISH | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
BEARISH 0 buys · 2 sells
Recent: Minor Lloyd sold 3282 sh @ $203.34 (2026-08-03); Minor Lloyd sold 2689 sh @ $200.96 (2026-08-04)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-20 · Asset managers net 901377 (-14458)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.